Drug Profile
Research programme: cancer metabolism therapeutics - Agios/Celgene
Alternative Names: AGI-14100; Glutaminase - Agios/Celgene; isocitrate dehydrogenase inhibitors - Agios/CelgeneLatest Information Update: 04 Dec 2019
Price :
$50
*
At a glance
- Originator Agios Pharmaceuticals
- Class Small molecules
- Mechanism of Action Glutamine inhibitors; Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors; Phosphofructokinase modulators; Pyruvate kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Brain cancer; Cancer; Myelodysplastic syndromes
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 14 Feb 2018 Agios Pharmaceuticals has issued patents and pending patents covering IDH mutant product candidates in countries worldwide
- 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)